NPS Postpones Preos Filing To Add Two-Year Data From PaTH Study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
NPS postpones Preos NDA filing to add two-year data from PaTH study. Submission was originally slated for year-end 2004. Firm says two-year results have implications for use of the osteoporosis agent with Fosamax (alendronate)